Latest & greatest articles for thyroid

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on thyroid or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on thyroid and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for thyroid

241. [A research on evidence-based healthcare for thyroid cancer screening. Part 1 : the current status of thyroid cancer screening]

[A research on evidence-based healthcare for thyroid cancer screening. Part 1 : the current status of thyroid cancer screening] [A research on evidence-based healthcare for thyroid cancer screening. Part 1 : the current status of thyroid cancer screening] [A research on evidence-based healthcare for thyroid cancer screening. Part 1 : the current status of thyroid cancer screening] Hyun MK, Kwon JW, Kim JH, Kim JM, Shim JI, Lee NR, Kim KW, Park YJ, Ahn HY, You MS Record Status (...) This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Hyun MK, Kwon JW, Kim JH, Kim JM, Shim JI, Lee NR, Kim KW, Park YJ, Ahn HY, You MS. [A research on evidence-based healthcare for thyroid cancer screening. Part 1 : the current status of thyroid cancer screening] . Seoul: National Evidence-based Healthcare Collaborating Agency (NECA). NECA-M-11-004. 2012 Authors' conclusions

2012 Health Technology Assessment (HTA) Database.

242. [Effectiveness of ultrasonographic screening for thyroid cancer]

[Effectiveness of ultrasonographic screening for thyroid cancer] [Effectiveness of ultrasonographic screening for thyroid cancer] [Effectiveness of ultrasonographic screening for thyroid cancer] Jang BH, Kim S, Sheen S, Kim YJ, Shin EH, Cho JJ, Park HA Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Jang BH, Kim S, Sheen S, Kim YJ, Shin (...) EH, Cho JJ, Park HA. [Effectiveness of ultrasonographic screening for thyroid cancer] Seoul: National Evidence-based Healthcare Collaborating Agency (NECA). NECA-M-11-004. 2012 Authors' conclusions A scale evaluating the effects of the USPSTF was used for this study to establish Key Questions 1~4. Key Question 1 : Would ultrasound thyroid screening and treatment raise the likelihood of early detection of thyroid cancer and reduce the risk of recurrence and death? 6 articles were chosen as final

2012 Health Technology Assessment (HTA) Database.

243. Regional differences in thyroid cancer incidence in Belgium: role of diagnostic and therapeutic strategies for thyroid disease

Regional differences in thyroid cancer incidence in Belgium: role of diagnostic and therapeutic strategies for thyroid disease Regional differences in thyroid cancer incidence in Belgium: role of diagnostic and therapeutic strategies for thyroid disease Regional differences in thyroid cancer incidence in Belgium: role of diagnostic and therapeutic strategies for thyroid disease Francart J, Van Den Bruel A, Decallonne B, Adam M, Dubois C, De Schutter H, Vlayen J, Stordeur S Record Status (...) This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Francart J, Van Den Bruel A, Decallonne B, Adam M, Dubois C, De Schutter H, Vlayen J, Stordeur S. Regional differences in thyroid cancer incidence in Belgium: role of diagnostic and therapeutic strategies for thyroid disease. Brussels: Belgian Health Care Knowledge Centre (KCE). KCE Report 177C. 2012 Authors' conclusions

2012 Health Technology Assessment (HTA) Database.

244. Thyroid cancer

Thyroid cancer Thyroidcancer:ESMOClinicalPracticeGuidelinesfor diagnosis,treatmentandfollow-up † F. Pacini 1 , M. G. Castagna 1 , L. Brilli 1 & G. Pentheroudakis 2 , on behalf of the ESMO Guidelines Working Group * 1 Department of Internal Medicine, Endocrinology and Metabolism and Biochemistry, Section of Endocrinology and Metabolism, University of Siena, Sienna, Italy; 2 Department of Medical Oncology, Medical School, University of Ioannina, Ioannina, Greece incidenceandepidemiology Thyroid (...) cancer is the most common of the endocrine malignancies and it represents 4 cm among men (1988–2005: APC 3.7) and women (1988–2005: APC 5.7) [4]. These data suggested that increased diagnostic scrutiny is not the only explanation, and environmental in?uence should also be considered. The only established environmental risk factor for thyroid carcinoma is exposure to ionizing radiation, and the risk, particularly of papillary carcinoma, is greater in subjects of younger age at exposure. An increased

2012 European Society for Medical Oncology

245. Strategies of radioiodine ablation in patients with low-risk thyroid cancer. Full Text available with Trip Pro

Strategies of radioiodine ablation in patients with low-risk thyroid cancer. It is not clear whether the administration of radioiodine provides any benefit to patients with low-risk thyroid cancer after a complete surgical resection. The administration of the smallest possible amount of radioiodine would improve care.In our randomized, phase 3 trial, we compared two thyrotropin-stimulation methods (thyroid hormone withdrawal and use of recombinant human thyrotropin) and two radioiodine ((131)I (...) ) doses (i.e., administered activities) (1.1 GBq and 3.7 GBq) in a 2-by-2 design. Inclusion criteria were an age of 18 years or older; total thyroidectomy for differentiated thyroid carcinoma; tumor-node-metastasis (TNM) stage, ascertained on pathological examination (p) of a surgical specimen, of pT1 (with tumor diameter ≤1 cm) and N1 or Nx, pT1 (with tumor diameter >1 to 2 cm) and any N stage, or pT2N0; absence of distant metastasis; and no iodine contamination. Thyroid ablation was assessed 8

2012 NEJM Controlled trial quality: uncertain

246. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. Full Text available with Trip Pro

Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. It is not known whether low-dose radioiodine (1.1 GBq [30 mCi]) is as effective as high-dose radioiodine (3.7 GBq [100 mCi]) for treating patients with differentiated thyroid cancer or whether the effects of radioiodine (especially at a low dose) are influenced by using either recombinant human thyrotropin (thyrotropin alfa) or thyroid hormone withdrawal.At 29 centers in the United Kingdom, we conducted a randomized (...) noninferiority trial comparing low-dose and high-dose radioiodine, each in combination with either thyrotropin alfa or thyroid hormone withdrawal before ablation. Patients (age range, 16 to 80 years) had tumor stage T1 to T3, with possible spread to nearby lymph nodes but without metastasis. End points were the rate of success of ablation at 6 to 9 months, adverse events, quality of life, and length of hospital stay.A total of 438 patients underwent randomization; data could be analyzed for 421. Ablation

2012 NEJM Controlled trial quality: predicted high

247. Antenatal thyroid screening and childhood cognitive function. Full Text available with Trip Pro

Antenatal thyroid screening and childhood cognitive function. Children born to women with low thyroid hormone levels have been reported to have decreased cognitive function.We conducted a randomized trial in which pregnant women at a gestation of 15 weeks 6 days or less provided blood samples for measurement of thyrotropin and free thyroxine (T(4)). Women were assigned to a screening group (in which measurements were obtained immediately) or a control group (in which serum was stored

2012 NEJM Controlled trial quality: predicted high

248. Surgical orbital decompression for thyroid eye disease. (Abstract)

Surgical orbital decompression for thyroid eye disease. Orbital decompression is an established procedure for the management of exophthalmos and visual rehabilitation from optic neuropathy in cases of thyroid eye disease. Numerous procedures for removal of orbital bony wall, fat or a combination of these for a variety of indications in different stages of the disease have been well reported in the medical literature. However, the relative effectiveness and safety of these procedures in relation (...) to the various indications remains unclear.To review current published evidence for the effectiveness of surgical orbital decompression for disfiguring proptosis in adult thyroid eye disease and summa rise information on possible complications and the quality of life from the studies identified.We searched CENTRAL (which contains the Cochrane Eyes and Vision Group Trials Register) (The Cochrane Library 2011, Issue 10), MEDLINE (January 1950 to October 2011), EMBASE (January 1980 to October 2011

2011 Cochrane

249. Should all papillary thyroid microcarcinomas be aggressively treated? An analysis of 18,445 cases (Abstract)

Should all papillary thyroid microcarcinomas be aggressively treated? An analysis of 18,445 cases The purpose of this study was to identify the risk factors that predict papillary thyroid microcarcinoma (PTMC)-related death in a large patient population to determine which patients need aggressive treatment.The management of PTMC is controversial and ranges from observation to total thyroidectomy. The lack of consensus is predominantly due to the general excellent overall prognosis, thereby (...) requiring a large cohort to delineate differences in outcome.All papillary thyroid cancer patients with tumor size of 1 cm or less in the Surveillance, Epidemiology and End Results Cancer Database from 1988 to 2007 were identified. Outcomes, including overall and disease-specific survival, were compared, and different risk groups were evaluated by multivariate analysis.A total of 18,445 cases of PTMC with surgery were identified. The 10-year and 15-year overall survivals were 94.6% and 90.7

2011 EvidenceUpdates

250. Use of radioactive iodine for thyroid cancer. Full Text available with Trip Pro

Use of radioactive iodine for thyroid cancer. Substantial uncertainty persists about the indications for radioactive iodine for thyroid cancer. Use of radioactive iodine over time and the correlates of its use remain unknown.To determine practice patterns, the degree to which hospitals vary in their use of radioactive iodine, and factors that contribute to this variation.Time trend analysis of radioactive iodine use in a cohort of 189,219 patients with well-differentiated thyroid cancer treated (...) at 981 hospitals associated with the US National Cancer Database between 1990 and 2008. We used multilevel analysis to assess the correlates of patient and hospital characteristics on radioactive iodine use in the cohort treated from 2004 to 2008.Use of radioactive iodine after total thyroidectomy.Between 1990 and 2008, across all tumor sizes, there was a significant increase in the proportion of patients with well-differentiated thyroid cancer receiving radioactive iodine (1373/3397 [40.4%] vs

2011 JAMA

251. Association between thyroid autoantibodies and miscarriage and preterm birth: meta-analysis of evidence

Association between thyroid autoantibodies and miscarriage and preterm birth: meta-analysis of evidence Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 DARE.

252. Ultrasound - Thyroid and Parathyroid

Ultrasound - Thyroid and Parathyroid Tel.: 613 860-3111 Fax: 613 860-3112 310-377 Dalhousie Street, Ottawa, Ontario K1N 9N8 CANADA www.car.ca info@car.ca CAR Standard for Performing Thyroid and Parathyroid Ultrasound Examinations Approved: April 28, 2011 Mostafa Atri; Cliff Levi; Lisl Mayer; Shia Salem, Chair; Ian Suchet; and Witek Zaleski. The standards of the Canadian Association of Radiologists (CAR) are not rules, but are guidelines that attempt to define principles of practice that should (...) , and deviation from a standard does not, in and of itself, indicate or imply that such medical practice is below an acceptable level of care. The ultimate judgment regarding the propriety of any specific procedure or course of conduct must be made by the physician and medical physicist in light of all circumstances presented by the individual situation. Canadian Association of Radiologists CAR Standard for Performing Thyroid and Parathyroid Ultrasound Examinations 2 TABLE OF CONTENTS I. INTRODUCTION 3 II

2011 Canadian Association of Radiologists

253. Randomized controlled trial of bilateral superficial cervical plexus block versus placebo in thyroid surgery Full Text available with Trip Pro

Randomized controlled trial of bilateral superficial cervical plexus block versus placebo in thyroid surgery Bilateral superficial cervical block during thyroid surgery can reduce postoperative pain but its value is unclear. This randomized clinical trial assessed the efficacy of such regional anaesthesia on postoperative pain after thyroid surgery performed under general anaesthesia.Patients undergoing thyroid surgery were randomized to one of four groups in a double-blind fashion. Patients (...) of hospital stay was the same in the bupivacaine and placebo groups (P = 0.925) and when bupivacaine was administered at the beginning or end of surgery (P = 0.087).Bilateral superficial cervical block with bupivacaine combined with general anaesthesia significantly reduced postoperative pain after thyroid surgery.NCT00472446 (http://www.clinicaltrials.gov).Copyright (c) 2010 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd. Copyright 2010 British Journal of Surgery Society Ltd

2010 EvidenceUpdates Controlled trial quality: predicted high

254. Long-term outcome in 215 children and adolescents with papillary thyroid cancer treated during 1940 through 2008 (Abstract)

Long-term outcome in 215 children and adolescents with papillary thyroid cancer treated during 1940 through 2008 Controversy exists regarding the aggressiveness of initial therapy in childhood papillary thyroid cancer (PTC). Few studies with long-term outcome exist and second primary malignancies have rarely been analyzed.We studied 215 PTC patients younger than 21 years old managed during 1940 through 2008. The patients were aged 3-20 year old (median age = 16 years); the median follow-up

2010 EvidenceUpdates

255. Which Thyroid Antibody Assays Should be Checked in Patients with Thyroid Disease?

Which Thyroid Antibody Assays Should be Checked in Patients with Thyroid Disease? Which Thyroid Antibody Assays Should be Checked in Patients with Thyroid Disease? – Clinical Correlations Search Which Thyroid Antibody Assays Should be Checked in Patients with Thyroid Disease? April 14, 2010 7 min read Michael Chu MD Faculty peer reviewed Case: A 44-year old female presented to the emergency room with complaints of a lower extremity rash and swelling. The patient had been in her usual state (...) believed to belong to a spectrum of diseases termed autoimmune thyroid diseases, of which Hashimoto’s thyroiditis, postpartum thyroiditis, silent thyroiditis, and atrophic autoimmune thyroiditis belong. The primary event in autoimmune thyroid diseases is likely T-cell mediated and many of the tissue consequences in both Graves’ and Hashimoto’s disease are caused by specific sub-sets of lymphocytes, lymphokines, as well as antibodies. The T-cell factors induce the B-cells to produce antibodies: Thyroid

2010 Clinical Correlations

256. Thyroid fine needle aspiration biopsy: is topical local anaesthesia beneficial? (Abstract)

Thyroid fine needle aspiration biopsy: is topical local anaesthesia beneficial? Thyroid fine needle aspiration biopsy (TFNAB) is the gold standard in the differential diagnosis of the thyroid nodules. In general, no analgesia is needed before this procedure. However, it is usually believed that the patients may be more comfortable if the procedure is performed under local anaesthetics. In this study, we examined the impact of the use of dermal anaesthetic on the patient's level of discomfort

2010 EvidenceUpdates Controlled trial quality: uncertain

257. Angiogenesis-inhibitors for metastatic thyroid cancer. (Abstract)

Angiogenesis-inhibitors for metastatic thyroid cancer. Systemic cytostatic therapies for advanced, metastatic thyroid carcinomas have been poorly effective. Tumor growth and metastasis depend on blood supply and blood vessel formation (angiogenesis). Therefore, inhibition of angiogenesis may represent a promising target for cancer therapy.To evaluate the benefits and risks of angiogenesis-inhibitors for metastatic thyroid cancer when given alone, or in combination with chemotherapy (...) advanced thyroid cancer.Two authors independently evaluated the search results against the selection criteria. Data extraction and risk of bias assessment were not performed because there were no studies that could be included.We did not identify any studies which met our full inclusion criteria.There is currently no reliable evidence available from randomized controlled trials regarding the bene fi ts and harms of the use of angiogenesis-inhibitors for treating advanced thyroid cancer. Several trials

2010 Cochrane

258. EANM procedure guidelines for therapy of benign thyroid disease

EANM procedure guidelines for therapy of benign thyroid disease GUIDELINES EANM procedure guidelines for therapy of benign thyroid disease Marcel P. M. Stokkel &Daria Handkiewicz Junak & Michael Lassmann &Markus Dietlein &Markus Luster Received: 16 June 2010/Accepted: 17 June 2010/Published online: 13 July 2010 # Springer-Verlag 2010 Abstract The purpose of the present guidelines on the 131 I therapy of benign thyroid disorders formulated by the European Association of Nuclear Medicine (EANM (...) ) Therapy Committee is to provide advice to nuclear medicine clinicians on how to treat benign thyroid conditions employing optimal 131 I activities. The recom- mendations were formulated based on recent literature and expert opinion regarding rationale, indications and contraindications for the use of 131 I procedures, as well as the adequate 131 I activities in different thyroid disorders, and the administration and patient preparation techniques to be used. Recommendations are also provided

2010 European Association of Nuclear Medicine

259. Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. Full Text available with Trip Pro

Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. Dyslipidemia increases the risk of atherosclerotic cardiovascular disease and is incompletely reversed by statin therapy alone in many patients. Thyroid hormone lowers levels of serum low-density lipoprotein (LDL) cholesterol and has other potentially favorable actions on lipoprotein metabolism. Consequently, thyromimetic drugs hold promise as lipid-lowering agents if adverse effects can be avoided.We performed (...) of serum apolipoprotein B, triglycerides, and Lp(a) lipoprotein. Eprotirome therapy was not associated with adverse effects on the heart or bone. No change in levels of serum thyrotropin or triiodothyronine was detected, although the thyroxine level decreased in patients receiving eprotirome.In this 12-week trial, the thyroid hormone analogue eprotirome was associated with decreases in levels of atherogenic lipoproteins in patients receiving treatment with statins. (ClinicalTrials.gov number

2010 NEJM Controlled trial quality: predicted high

260. Use of color Doppler ultrasonography for the prediction of malignancy in follicular thyroid neoplasms: systematic review and meta-analysis

Use of color Doppler ultrasonography for the prediction of malignancy in follicular thyroid neoplasms: systematic review and meta-analysis Use of color Doppler ultrasonography for the prediction of malignancy in follicular thyroid neoplasms: systematic review and meta-analysis Use of color Doppler ultrasonography for the prediction of malignancy in follicular thyroid neoplasms: systematic review and meta-analysis Iared W, Shigueoka DC, Cristofoli JC, Andriolo R, Atallah AN, Ajzen SA, Valente O (...) CRD summary This review concluded that predominant internal flow seen on colour Doppler ultrasound was associated with malignancy of thyroid follicular neoplasms; absence of internal flow or predominantly peripheral flow indicated low probability of malignancy. The small number and relatively poor quality of included studies and lack of reporting of analytical methods mean that these conclusions should be interpreted cautiously. Authors' objectives To assess the diagnostic accuracy of colour

2010 DARE.